KATHERINE: T-DM1 for HER2+ Residual Disease — Mobile Quick Reference

Save for clinic

📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications

🎯 Clinical Bottom Line

KATHERINE demonstrated that switching to T-DM1 for 14 cycles of adjuvant therapy halves the risk of invasive disease recurrence or death in patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant chemotherapy with trastuzumab. The benefit was consistent across all subgroups, including patients who received neoadjuvant pertuzumab. This is the standard of care for this population.

Key Result: 3-year IDFS — 88.3% vs 77.0%, HR 0.50 (95% CI 0.39–0.64; P<0.001)

Safety Signal: Thrombocytopenia is the critical toxicity (grade ≥3: 5.7%); one fatal intracranial hemorrhage occurred after a fall in a patient with a platelet count of 55,000/mm³. Discontinuation rate: 18.0% with T-DM1 vs 2.1% with trastuzumab.

✅ Patient Eligibility

Must Have:

• HER2-positive (centrally confirmed)
• Residual invasive disease in breast or axilla at surgery after neoadjuvant therapy
• Completed ≥6 cycles (16 weeks) preoperative chemo with ≥9 weeks taxane + ≥9 weeks trastuzumab
• Clinical stage T1–T4, N0–N3, M0 (excluding T1aN0 or T1bN0)

Cannot Have:

• Gross residual disease after mastectomy or positive margins after BCS
• Disease progression during neoadjuvant therapy
• Heart failure NYHA class ≥II or history of LVEF <40%

💊 Dosing Quick Guide

Experimental Regimen

T-DM1: 3.6 mg/kg IV every 3 weeks Cycle: 21 days Duration: 14 cycles

Control Regimen

Trastuzumab: 6 mg/kg IV every 3 weeks (loading dose 8 mg/kg if >6 weeks since last dose) Duration: 14 cycles

Key Dose Modifications [2]

Per FDA prescribing information — not trial protocol - Dose reduction levels: 3.0 mg/kg → 2.4 mg/kg; discontinue if further reduction required [2] - Hold for platelets <50,000/mm³ or AST/ALT >5× ULN; permanently discontinue for platelets <25,000/mm³ or AST/ALT >20× ULN [2] - Monitor platelets and LFTs prior to each dose [2]

Mechanism: T-DM1 is an antibody-drug conjugate that combines trastuzumab with the cytotoxic agent DM1 (maytansine derivative), delivering the microtubule inhibitor directly to HER2-overexpressing cells after receptor-mediated internalization [2].

⚠️ Safety Snapshot

⚠️ Decreased platelet count: Any grade 28.5%, Grade ≥3 5.7%, Fatal 0.1% (1 intracranial hemorrhage after fall)

Key safety metrics:

• Discontinuations due to AE: 18.0% vs 2.1%
• Serious AEs: 12.7% vs 8.1%
• Dose reductions (T-DM1): 10.4% one level, 3.9% two levels
• Grade 5 AE: 1 (0.1%) T-DM1 vs 0 trastuzumab

📊 Key Numbers

Median follow-up: 41.4 months (T-DM1); 40.9 months (trastuzumab)

OS boundary not crossed at this interim analysis (boundary: P<0.000032). Three additional OS analyses planned.

🔬 Key Comparator Context

Cross-trial comparisons are limited by differences in populations, designs, and endpoints.

🔍 Subgroups to Watch

HR-negative: HR 0.50 (95% CI 0.33–0.74) — benefit consistent regardless of hormone-receptor status HR-positive: HR 0.48 (95% CI 0.35–0.67) — similar magnitude of benefit in HR+ population Neoadjuvant trastuzumab alone: HR 0.49 (95% CI 0.37–0.65) — robust benefit in the majority subgroup Neoadjuvant trastuzumab + additional HER2 agent: HR 0.54 (95% CI 0.27–1.06) — CI crosses 1.0 but small n; pertuzumab subset HR 0.50 (0.25–1.00) Node-positive: HR 0.52 (95% CI 0.38–0.71) — benefit in higher-risk nodal disease Node-negative or NE: HR 0.44 (95% CI 0.28–0.68) — benefit maintained in node-negative patients Residual disease ≤1 cm + N−: HR 0.60 (95% CI 0.33–1.12) — point estimate favors T-DM1 but CI crosses 1.0 in this exploratory analysis (n=331)

Subgroup analyses were not powered for formal comparisons. Results are hypothesis-generating.

📋 Regulatory Status

⚠️ Verify current regulatory status before prescribing.

NCCN: Preferred adjuvant regimen for HER2+ EBC with residual invasive disease after neoadjuvant therapy — Category 1 [3]

⚡ Grey Zones

• Patients achieving pCR after neoadjuvant therapy were not studied — no data to support T-DM1 in that population
• Whether a shorter course of T-DM1 (<14 cycles) preserves efficacy with less toxicity is unknown
• Patients with minimal residual disease (≤1 cm, N−) may derive smaller absolute benefit — judgment call on toxicity trade-off
• Optimal sequencing with extended adjuvant neratinib after T-DM1 has not been prospectively studied

📖 Full Analysis

Read the complete desktop article with full efficacy tables, safety detail, subgroup data, comparator trials, and clinical implications at kill-cancer.com

About the Author

Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.

📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum

For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.

References

1. von Minckwitz G, Huang C-S, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380:617-628. doi:10.1056/NEJMoa1814017
2. Kadcyla (ado-trastuzumab emtansine) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
3. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N Engl J Med. 2005;353:1659-1672. doi:10.1056/NEJMoa052306
5. Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET). Lancet Oncol. 2017;18:1688-1700. doi:10.1016/S1470-2045(17)30717-9